{"success":true,"data":{"pressRelease":{"id":"155103","rtpr_id":"nPn3mP0JCa-20260929","ticker":"IMCC","exchange":"NASDAQ","all_tickers":["IMCC"],"title":"IM Cannabis Announces Closing of the Sale of IMC Holdings and Its European-Focused Operations, Strengthens Balance Sheet","author":"PR Newswire","published_at":"2026-09-29T11:07:00.288Z","article_body":"IM Cannabis Announces Closing of the Sale of IMC Holdings and Its European-Focused Operations, Strengthens Balance Sheet\nPR Newswire\n\nVANCOUVER, BC and GLIL YAM, Israel, Sept. 29, 2026\n\nTransaction Expected to Result in an Improvement of Approximately C$3 Million\nin Shareholders' Equity\n\nVANCOUVER, BC and GLIL YAM, Israel, Sept. 29, 2026 /PRNewswire/ -- IM Cannabis\nCorp. (the \"Company\") (NASDAQ: IMCC), today announced that, further to its\npress releases dated June 18, 2026 and August 17, 2026, it has completed the\npreviously announced transaction contemplated by the definitive share purchase\nagreement dated August 16, 2026 (the \"Share Purchase Agreement\") among the\nCompany, Slil.com Holding Ltd. (\"Slil\") and I.M.C. Holdings Ltd. (\"IMC\nHoldings\"), pursuant to which the Company sold to Slil all of the issued and\noutstanding shares of IMC Holdings (the \"Transaction\"). The Transaction closed\non September 29, 2026 following satisfaction or waiver, as applicable, of the\nconditions to closing under the Share Purchase Agreement.\n\nPrior to closing, IMC Holdings completed a pre-closing reorganization pursuant\nto which the Company's Israeli operations were transferred out of IMC Holdings\nand retained by the Company. Following completion of the pre-closing\nreorganization, IMC Holdings held, as its only material assets, its direct or\nindirect equity interests in Adjupharm GmbH, Xinteza API Ltd. and Shiran\nSociete Anonyme (together, the \"Target Subsidiaries\"), together with certain\nliabilities that remained in IMC Holdings immediately prior to closing and\ncontinued to be obligations of IMC Holdings following Slil's acquisition of\nIMC Holdings (the \"Retained Liabilities\").\n\nThe Company expects the Transaction to improve its shareholders' equity and\nworking capital, reduce the liabilities reflected in the Company's\nconsolidated financial position that are associated with IMC Holdings, and\nstreamline the Company's corporate structure. Following completion of the\nTransaction, the Company intends to focus its resources on its retained\nIsraeli medical cannabis operations while continuing to evaluate additional\nopportunities. Based on management's current unaudited pro forma analysis, the\nCompany expects the Transaction to result in an improvement of approximately\nC$3 million in shareholders' equity. The actual accounting impact of the\nTransaction may differ from this estimate and will be reflected in the\nCompany's financial statements for the applicable reporting period.\n\nThe consideration for the Transaction consisted of a C$3,000,000 advance\npayment previously made by Slil to the Company, receipt of which is\nacknowledged in the Share Purchase Agreement, together with Slil's acquisition\nof IMC Holdings with the Retained Liabilities remaining in IMC Holdings. Under\nthe Share Purchase Agreement, the aggregate Retained Liabilities of IMC\nHoldings were not to exceed C$9,400,000, subject to adjustment by mutual\nagreement of the parties. This amount excludes direct liabilities of the\nTarget Subsidiaries, to which the C$9,400,000 cap does not apply. No\nsecurities of the Company or IMC Holdings were issued or exchanged as\nconsideration in connection with the Transaction.\n\nIn connection with the Transaction, the board of directors of the Company (the\n\"Board\") established a special committee comprised solely of independent\ndirectors (the \"Special Committee\") to review, consider and evaluate the\nTransaction. The Special Committee reviewed the terms of the Transaction and\nrecommended that the Board approve the Transaction. Oren Shuster declared his\ninterest in the Transaction and did not participate in or vote on its\napproval. In addition, Beta Finance T.Y.S Ltd., an arm's-length financial\nconsulting firm engaged by the Board, provided a financial analysis to assist\nthe Special Committee and the Board in evaluating the Transaction.\n\nRelated Party Transaction and MI 61-101\n\nThe Transaction constituted a \"related party transaction\" within the meaning\nof Multilateral Instrument 61-101 – Protection of Minority Security Holders\nin Special Transactions (\"MI 61-101\") because Slil is beneficially owned and\ncontrolled by Oren Shuster, the Company's Chief Executive Officer, a director,\nsecurityholder and debtholder.\n\nIn connection with the Transaction, the Company relied on the financial\nhardship exemptions from the formal valuation requirement and minority\napproval requirement under sections 5.5(g) and 5.7(1)(e) of MI 61-101,\nrespectively. The Company relied on these exemptions on the basis that, among\nother things: (i) the Company was in serious financial difficulty; (ii) the\nTransaction was designed to improve the financial position of the Company;\n(iii) the circumstances described in section 5.5(f) of MI 61-101 were not\napplicable; (iv) the Board, acting in good faith, and at least two-thirds of\nthe Company's independent directors, acting in good faith, determined that\nparagraphs (i) and (ii) applied and that the terms of the Transaction were\nreasonable in the circumstances of the Company; and (v) there was no\nrequirement, corporate or otherwise, to hold a meeting to obtain approval of\nthe holders of any class of affected securities. Although the Company relied\non the financial hardship exemption from the formal valuation requirement\nunder MI 61-101, the financial analysis provided by Beta Finance T.Y.S Ltd did\nnot constitute a \"formal valuation\" within the meaning of MI 61-101. Further\ndetails regarding the completion of the Transaction will be provided in a\nmaterial change report to be filed by the Company in accordance with\napplicable securities laws.\n\nAbout IM Cannabis Corp.\n\nIM Cannabis Corp. (NASDAQ: IMCC) is an international company operating a\nmedical cannabis platform serving patients in Israel.\n\nThe Company's ecosystem operates in Israel through its subsidiaries, which\nimport and distribute cannabis to medical patients, leveraging years of\nproprietary data and patient insights. The Company also operates medical\ncannabis retail pharmacies and online platforms in Israel that enable the safe\ndelivery and quality control of IMCC's products throughout the value chain.\n\nDisclaimer for Forward-Looking Statements\n\nThis press release contains forward-looking information or forward-looking\nstatements under applicable Canadian and United States securities laws\n(collectively, \"forward-looking statements\"). Forward-looking statements are\noften, but not always, identified by words such as \"may\", \"will\", \"could\",\n\"would\", \"should\", \"expect\", \"intend\", \"anticipate\", \"believe\", \"plan\",\n\"estimate\", \"likely\", \"potential\", \"proposed\" and similar expressions, or\nstatements that events, conditions or results \"may\", \"will\", \"could\", \"would\"\nor \"should\" occur or be achieved.\n\nForward-looking statements in this press release include, without limitation,\nstatements concerning the anticipated effect of the Transaction on the\nCompany's shareholders' equity, working capital, consolidated liabilities,\ncorporate structure and financial condition; the Company's intended focus on\nits retained Israeli medical cannabis operations; the Company's evaluation of\nadditional opportunities; the anticipated accounting treatment and financial\nimpact of the Transaction; and the realization of the expected financial and\noperational benefits of the Transaction.\n\nForward-looking statements are based on a number of assumptions, including\nthat the Company's preliminary and unaudited estimates regarding the\naccounting and financial impact of the Transaction are materially accurate;\nthat the accounting treatment of the Transaction will be consistent with\nmanagement's current expectations; that the Company will realize the expected\nbenefits of the Transaction; that no unanticipated liabilities,\nindemnification obligations, tax liabilities or post-closing claims will\nmaterially reduce those anticipated benefits; and that the Company will be\nable to operate and finance its retained Israeli business substantially as\ncurrently contemplated.\n\nForward-looking statements are subject to known and unknown risks,\nuncertainties and other factors that may cause actual results, events or\ndevelopments to differ materially from those expressed or implied by such\nstatements. These risks and uncertainties include, without limitation: the\nrisk that the anticipated improvement in shareholders' equity, working\ncapital, consolidated liabilities, corporate structure or financial condition\nis not realized or is less than expected; the risk that the accounting\ntreatment or financial impact of the Transaction differs from management's\ncurrent expectations; the risk of purchase-price adjustments, post-closing\nclaims, indemnification obligations, tax liabilities or disputes arising from\nthe Transaction or the pre-closing reorganization; the risk that liabilities\nassociated with IMC Holdings or the Target Subsidiaries differ from the\namounts currently expected; the risk that the retained Israeli operations do\nnot perform as expected; risks relating to the Company's liquidity position,\ngoing concern disclosure, debt obligations and ability to raise additional\ncapital; the risk that the Company is unable to maintain or regain compliance\nwith the continued listing requirements of Nasdaq Stock Market LLC; risks\nrelating to regulatory changes, licensing, supply-chain constraints,\ncompetition, product liability and reliance on key personnel; war, conflict\nand civil unrest in Israel and the Middle East; and the other risks,\nuncertainties and factors described under the heading \"Risk Factors\" in the\nCompany's annual report for the year ended December 31, 2025 and in the\nCompany's subsequent public filings, which are available under the Company's\nissuer profile on SEDAR+ at www.sedarplus.ca (https://www.sedarplus.ca/)  and\nEDGAR at www.sec.gov/edgar (https://www.sec.gov/edgar) .\n\nForward-looking statements are made as of the date of this press release and\nare based on the beliefs, estimates, expectations and opinions of management\non the date such statements are made. The Company does not undertake any\nobligation to update any forward-looking statements, except as required by\napplicable securities laws. Investors should not place undue reliance on\nforward-looking statements. The forward-looking statements contained in this\npress release are expressly qualified by this cautionary statement.\n\nCompany Contact:\nMichal Efraty\nInvestor & Public Relations\nmichal@efraty.com (mailto:michal@efraty.com)\n\nOren Shuster, CEO\nIM Cannabis Corp.\ninfo@imcannabis.com (mailto:info@imcannabis.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/im-cannabis-announces-closing-of-the-sale-of-imc-holdings-and-its-european-focused-operations-strengthens-balance-sheet-302892793.html\n(https://www.prnewswire.com/news-releases/im-cannabis-announces-closing-of-the-sale-of-imc-holdings-and-its-european-focused-operations-strengthens-balance-sheet-302892793.html)\n\nSOURCE IM Cannabis Corp.\n\n\n\nFor media only: +972-77-3603504\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1326844/IM-Cannabis-Logo.jpg?id=OA2976316\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn3mP0JCa-20260929","title":"IM Cannabis Announces Closing of the Sale of IMC Holdings and Its European-Focused Operations, Strengthens Balance Sheet","author":"PR Newswire","ticker":"IMCC","created":"2026-09-29T11:07:00.288Z","tickers":["IMCC"],"exchange":"NASDAQ","article_body":"IM Cannabis Announces Closing of the Sale of IMC Holdings and Its European-Focused Operations, Strengthens Balance Sheet\nPR Newswire\n\nVANCOUVER, BC and GLIL YAM, Israel, Sept. 29, 2026\n\nTransaction Expected to Result in an Improvement of Approximately C$3 Million\nin Shareholders' Equity\n\nVANCOUVER, BC and GLIL YAM, Israel, Sept. 29, 2026 /PRNewswire/ -- IM Cannabis\nCorp. (the \"Company\") (NASDAQ: IMCC), today announced that, further to its\npress releases dated June 18, 2026 and August 17, 2026, it has completed the\npreviously announced transaction contemplated by the definitive share purchase\nagreement dated August 16, 2026 (the \"Share Purchase Agreement\") among the\nCompany, Slil.com Holding Ltd. (\"Slil\") and I.M.C. Holdings Ltd. (\"IMC\nHoldings\"), pursuant to which the Company sold to Slil all of the issued and\noutstanding shares of IMC Holdings (the \"Transaction\"). The Transaction closed\non September 29, 2026 following satisfaction or waiver, as applicable, of the\nconditions to closing under the Share Purchase Agreement.\n\nPrior to closing, IMC Holdings completed a pre-closing reorganization pursuant\nto which the Company's Israeli operations were transferred out of IMC Holdings\nand retained by the Company. Following completion of the pre-closing\nreorganization, IMC Holdings held, as its only material assets, its direct or\nindirect equity interests in Adjupharm GmbH, Xinteza API Ltd. and Shiran\nSociete Anonyme (together, the \"Target Subsidiaries\"), together with certain\nliabilities that remained in IMC Holdings immediately prior to closing and\ncontinued to be obligations of IMC Holdings following Slil's acquisition of\nIMC Holdings (the \"Retained Liabilities\").\n\nThe Company expects the Transaction to improve its shareholders' equity and\nworking capital, reduce the liabilities reflected in the Company's\nconsolidated financial position that are associated with IMC Holdings, and\nstreamline the Company's corporate structure. Following completion of the\nTransaction, the Company intends to focus its resources on its retained\nIsraeli medical cannabis operations while continuing to evaluate additional\nopportunities. Based on management's current unaudited pro forma analysis, the\nCompany expects the Transaction to result in an improvement of approximately\nC$3 million in shareholders' equity. The actual accounting impact of the\nTransaction may differ from this estimate and will be reflected in the\nCompany's financial statements for the applicable reporting period.\n\nThe consideration for the Transaction consisted of a C$3,000,000 advance\npayment previously made by Slil to the Company, receipt of which is\nacknowledged in the Share Purchase Agreement, together with Slil's acquisition\nof IMC Holdings with the Retained Liabilities remaining in IMC Holdings. Under\nthe Share Purchase Agreement, the aggregate Retained Liabilities of IMC\nHoldings were not to exceed C$9,400,000, subject to adjustment by mutual\nagreement of the parties. This amount excludes direct liabilities of the\nTarget Subsidiaries, to which the C$9,400,000 cap does not apply. No\nsecurities of the Company or IMC Holdings were issued or exchanged as\nconsideration in connection with the Transaction.\n\nIn connection with the Transaction, the board of directors of the Company (the\n\"Board\") established a special committee comprised solely of independent\ndirectors (the \"Special Committee\") to review, consider and evaluate the\nTransaction. The Special Committee reviewed the terms of the Transaction and\nrecommended that the Board approve the Transaction. Oren Shuster declared his\ninterest in the Transaction and did not participate in or vote on its\napproval. In addition, Beta Finance T.Y.S Ltd., an arm's-length financial\nconsulting firm engaged by the Board, provided a financial analysis to assist\nthe Special Committee and the Board in evaluating the Transaction.\n\nRelated Party Transaction and MI 61-101\n\nThe Transaction constituted a \"related party transaction\" within the meaning\nof Multilateral Instrument 61-101 – Protection of Minority Security Holders\nin Special Transactions (\"MI 61-101\") because Slil is beneficially owned and\ncontrolled by Oren Shuster, the Company's Chief Executive Officer, a director,\nsecurityholder and debtholder.\n\nIn connection with the Transaction, the Company relied on the financial\nhardship exemptions from the formal valuation requirement and minority\napproval requirement under sections 5.5(g) and 5.7(1)(e) of MI 61-101,\nrespectively. The Company relied on these exemptions on the basis that, among\nother things: (i) the Company was in serious financial difficulty; (ii) the\nTransaction was designed to improve the financial position of the Company;\n(iii) the circumstances described in section 5.5(f) of MI 61-101 were not\napplicable; (iv) the Board, acting in good faith, and at least two-thirds of\nthe Company's independent directors, acting in good faith, determined that\nparagraphs (i) and (ii) applied and that the terms of the Transaction were\nreasonable in the circumstances of the Company; and (v) there was no\nrequirement, corporate or otherwise, to hold a meeting to obtain approval of\nthe holders of any class of affected securities. Although the Company relied\non the financial hardship exemption from the formal valuation requirement\nunder MI 61-101, the financial analysis provided by Beta Finance T.Y.S Ltd did\nnot constitute a \"formal valuation\" within the meaning of MI 61-101. Further\ndetails regarding the completion of the Transaction will be provided in a\nmaterial change report to be filed by the Company in accordance with\napplicable securities laws.\n\nAbout IM Cannabis Corp.\n\nIM Cannabis Corp. (NASDAQ: IMCC) is an international company operating a\nmedical cannabis platform serving patients in Israel.\n\nThe Company's ecosystem operates in Israel through its subsidiaries, which\nimport and distribute cannabis to medical patients, leveraging years of\nproprietary data and patient insights. The Company also operates medical\ncannabis retail pharmacies and online platforms in Israel that enable the safe\ndelivery and quality control of IMCC's products throughout the value chain.\n\nDisclaimer for Forward-Looking Statements\n\nThis press release contains forward-looking information or forward-looking\nstatements under applicable Canadian and United States securities laws\n(collectively, \"forward-looking statements\"). Forward-looking statements are\noften, but not always, identified by words such as \"may\", \"will\", \"could\",\n\"would\", \"should\", \"expect\", \"intend\", \"anticipate\", \"believe\", \"plan\",\n\"estimate\", \"likely\", \"potential\", \"proposed\" and similar expressions, or\nstatements that events, conditions or results \"may\", \"will\", \"could\", \"would\"\nor \"should\" occur or be achieved.\n\nForward-looking statements in this press release include, without limitation,\nstatements concerning the anticipated effect of the Transaction on the\nCompany's shareholders' equity, working capital, consolidated liabilities,\ncorporate structure and financial condition; the Company's intended focus on\nits retained Israeli medical cannabis operations; the Company's evaluation of\nadditional opportunities; the anticipated accounting treatment and financial\nimpact of the Transaction; and the realization of the expected financial and\noperational benefits of the Transaction.\n\nForward-looking statements are based on a number of assumptions, including\nthat the Company's preliminary and unaudited estimates regarding the\naccounting and financial impact of the Transaction are materially accurate;\nthat the accounting treatment of the Transaction will be consistent with\nmanagement's current expectations; that the Company will realize the expected\nbenefits of the Transaction; that no unanticipated liabilities,\nindemnification obligations, tax liabilities or post-closing claims will\nmaterially reduce those anticipated benefits; and that the Company will be\nable to operate and finance its retained Israeli business substantially as\ncurrently contemplated.\n\nForward-looking statements are subject to known and unknown risks,\nuncertainties and other factors that may cause actual results, events or\ndevelopments to differ materially from those expressed or implied by such\nstatements. These risks and uncertainties include, without limitation: the\nrisk that the anticipated improvement in shareholders' equity, working\ncapital, consolidated liabilities, corporate structure or financial condition\nis not realized or is less than expected; the risk that the accounting\ntreatment or financial impact of the Transaction differs from management's\ncurrent expectations; the risk of purchase-price adjustments, post-closing\nclaims, indemnification obligations, tax liabilities or disputes arising from\nthe Transaction or the pre-closing reorganization; the risk that liabilities\nassociated with IMC Holdings or the Target Subsidiaries differ from the\namounts currently expected; the risk that the retained Israeli operations do\nnot perform as expected; risks relating to the Company's liquidity position,\ngoing concern disclosure, debt obligations and ability to raise additional\ncapital; the risk that the Company is unable to maintain or regain compliance\nwith the continued listing requirements of Nasdaq Stock Market LLC; risks\nrelating to regulatory changes, licensing, supply-chain constraints,\ncompetition, product liability and reliance on key personnel; war, conflict\nand civil unrest in Israel and the Middle East; and the other risks,\nuncertainties and factors described under the heading \"Risk Factors\" in the\nCompany's annual report for the year ended December 31, 2025 and in the\nCompany's subsequent public filings, which are available under the Company's\nissuer profile on SEDAR+ at www.sedarplus.ca (https://www.sedarplus.ca/)  and\nEDGAR at www.sec.gov/edgar (https://www.sec.gov/edgar) .\n\nForward-looking statements are made as of the date of this press release and\nare based on the beliefs, estimates, expectations and opinions of management\non the date such statements are made. The Company does not undertake any\nobligation to update any forward-looking statements, except as required by\napplicable securities laws. Investors should not place undue reliance on\nforward-looking statements. The forward-looking statements contained in this\npress release are expressly qualified by this cautionary statement.\n\nCompany Contact:\nMichal Efraty\nInvestor & Public Relations\nmichal@efraty.com (mailto:michal@efraty.com)\n\nOren Shuster, CEO\nIM Cannabis Corp.\ninfo@imcannabis.com (mailto:info@imcannabis.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/im-cannabis-announces-closing-of-the-sale-of-imc-holdings-and-its-european-focused-operations-strengthens-balance-sheet-302892793.html\n(https://www.prnewswire.com/news-releases/im-cannabis-announces-closing-of-the-sale-of-imc-holdings-and-its-european-focused-operations-strengthens-balance-sheet-302892793.html)\n\nSOURCE IM Cannabis Corp.\n\n\n\nFor media only: +972-77-3603504\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1326844/IM-Cannabis-Logo.jpg?id=OA2976316\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-29T11:07:00.399959573Z","server_sent_at_ms":1790680020399},"received_at":"2026-09-29T11:07:00.451Z","source_url":"https://www.prnewswire.com/news-releases/im-cannabis-announces-closing-of-the-sale-of-imc-holdings-and-its-european-focused-operations-strengthens-balance-sheet-302892793.html"},"analysis":{"id":"143845","press_release_id":"155103","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["related-party transaction: acquirer Slil is owned and controlled by CEO Oren Shuster","reliance on financial-hardship exemptions (MI 61-101 sections 5.5(g) and 5.7(1)(e)) indicates the company is in serious financial difficulty","no formal valuation obtained — Beta Finance analysis was not a formal valuation","going-concern disclosure and Nasdaq continued-listing compliance risks referenced in forward-looking statements"],"eventType":"m_and_a","narrative":"IM Cannabis closed the sale of IMC Holdings and its European-focused operations (Adjupharm, Xinteza API, Shiran) to Slil.com Holding on September 29, 2026.\n\nConsideration consisted of a C$3,000,000 advance payment plus Slil assuming IMC Holdings with retained liabilities capped at C$9,400,000; the Company expects roughly C$3 million of improvement in shareholders' equity and no securities were issued.\n\nThe buyer is beneficially owned by CEO Oren Shuster, making this a related-party transaction under MI 61-101, for which the Company relied on financial-hardship exemptions from formal valuation and minority approval — an explicit admission it was in serious financial difficulty.\n\nPost-divestiture, IMCC will focus on its retained Israeli medical cannabis operations while continuing to evaluate additional opportunities.","sentiment":"mixed","agentHooks":{"shouldPost":true,"suggestedAngle":"Balance-sheet cleanup via CEO-affiliated buyer closes, but the financial-hardship exemption exposes the company's distress and related-party optics."},"keyFigures":{"customDimensions":{"advance_payment":"C$3,000,000","retained_liabilities_cap":"C$9,400,000","shareholders_equity_improvement":"approximately C$3 million"}},"quotedText":"The Transaction constituted a \"related party transaction\" within the meaning of Multilateral Instrument 61-101","namedEntities":{"people":[{"name":"Oren Shuster","role":"CEO, director, securityholder and debtholder; buyer-side interested party"}],"products":[],"companies":[{"name":"IM Cannabis Corp.","ticker":"IMCC","relationship":"filer/seller"},{"name":"Slil.com Holding Ltd.","relationship":"acquirer"},{"name":"I.M.C. Holdings Ltd.","relationship":"target/divested subsidiary"},{"name":"Adjupharm GmbH","relationship":"divested subsidiary"},{"name":"Xinteza API Ltd.","relationship":"divested subsidiary"},{"name":"Shiran Societe Anonyme","relationship":"divested subsidiary"},{"name":"Beta Finance T.Y.S Ltd.","relationship":"financial consultant to the Board"}],"dollarAmounts":[{"amount":"C$3,000,000","context":"advance payment made by Slil to the Company as consideration"},{"amount":"C$3 million","context":"expected improvement in shareholders' equity"},{"amount":"C$9,400,000","context":"cap on aggregate Retained Liabilities of IMC Holdings"}]},"materialImpact":{"score":3,"reasoning":"Closing of a divestiture that improves shareholders' equity by ~C$3 million and removes European operations, but the sale was a related-party transaction with the CEO using financial-hardship exemptions, signaling the company was in serious financial difficulty."},"tickerRelevance":{"others":[],"primary":"IMCC"},"globalImportance":25,"audienceRelevance":15,"eventTypeSecondary":["restructuring"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"closed divestiture with related-party elements","distressSignal":"financial-hardship exemption","householdBrandBoost":0}},"event_type":"m_and_a","event_type_secondary":["restructuring"],"sentiment":"mixed","material_impact_score":3,"narrative":"IM Cannabis closed the sale of IMC Holdings and its European-focused operations (Adjupharm, Xinteza API, Shiran) to Slil.com Holding on September 29, 2026.\n\nConsideration consisted of a C$3,000,000 advance payment plus Slil assuming IMC Holdings with retained liabilities capped at C$9,400,000; the Company expects roughly C$3 million of improvement in shareholders' equity and no securities were issued.\n\nThe buyer is beneficially owned by CEO Oren Shuster, making this a related-party transaction under MI 61-101, for which the Company relied on financial-hardship exemptions from formal valuation and minority approval — an explicit admission it was in serious financial difficulty.\n\nPost-divestiture, IMCC will focus on its retained Israeli medical cannabis operations while continuing to evaluate additional opportunities.","key_figures":{"customDimensions":{"advance_payment":"C$3,000,000","retained_liabilities_cap":"C$9,400,000","shareholders_equity_improvement":"approximately C$3 million"}},"named_entities":{"people":[{"name":"Oren Shuster","role":"CEO, director, securityholder and debtholder; buyer-side interested party"}],"products":[],"companies":[{"name":"IM Cannabis Corp.","ticker":"IMCC","relationship":"filer/seller"},{"name":"Slil.com Holding Ltd.","relationship":"acquirer"},{"name":"I.M.C. Holdings Ltd.","relationship":"target/divested subsidiary"},{"name":"Adjupharm GmbH","relationship":"divested subsidiary"},{"name":"Xinteza API Ltd.","relationship":"divested subsidiary"},{"name":"Shiran Societe Anonyme","relationship":"divested subsidiary"},{"name":"Beta Finance T.Y.S Ltd.","relationship":"financial consultant to the Board"}],"dollarAmounts":[{"amount":"C$3,000,000","context":"advance payment made by Slil to the Company as consideration"},{"amount":"C$3 million","context":"expected improvement in shareholders' equity"},{"amount":"C$9,400,000","context":"cap on aggregate Retained Liabilities of IMC Holdings"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T11:07:13.894Z","global_importance":25,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"closed divestiture with related-party elements","distressSignal":"financial-hardship exemption","householdBrandBoost":0}},"durationMs":13426,"modelName":"glm-5.3-flashx"}}